Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group - PubMed (original) (raw)

Clinical Trial

. 1998 May;177(5):1230-46.

doi: 10.1086/515288.

K Weinhold, T J Matthews, B S Graham, G J Gorse, M C Keefer, M J McElrath, R H Hsieh, J Mestecky, S Zolla-Pazner, J Mascola, D Schwartz, R Siliciano, L Corey, P F Wright, R Belshe, R Dolin, S Jackson, S Xu, P Fast, M C Walker, D Stablein, J L Excler, J Tartaglia, E Paoletti, et al.

Affiliations

• PMID: 9593008
• DOI: 10.1086/515288

Clinical Trial

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group

M L Clements-Mann et al. J Infect Dis. 1998 May.

Abstract

A safety and immunogenicity trial was conducted in vaccinia-immune and vaccinia-naive human immunodeficiency virus (HIV)-uninfected adults who were randomized to receive 10(6) or 10(7) TCID50 of canarypox (ALVAC) vector expressing HIV-1MN gp160 or 10(5.5) TCID50 of ALVAC-rabies virus glycoprotein control at 0 and 1 or 2 months and ALVAC-gp160 or 50 microg of HIV-1SF2 recombinant (r) gp120 in microfluidized emulsion at 9 and 12 months; others received rgp120 at 0, 1, 6, and 12 months. All vaccines were well-tolerated. Neither vaccinia-immune status before vaccination nor ALVAC dose affected HIV immune responses. HIV-1MN and HIV-1SF2 neutralizing antibodies were detected more often (100%) in ALVAC-gp160/rgp120 recipients than in recipients of ALVAC-gp160 (<65%) or rgp120 (89%) alone. ALVAC-gp160/rgp120 also elicited more frequent HIV V3-specific and fusion-inhibition antibodies, antibody-dependent cellular cytotoxicity, lymphoproliferation, and cytotoxic CD8+ T cell activity than did either vaccine alone. Trials with ALVAC expressing additional HIV components and rgp120 are underway.

PubMed Disclaimer

Similar articles

• Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.
  Belshe RB, Gorse GJ, Mulligan MJ, Evans TG, Keefer MC, Excler JL, Duliege AM, Tartaglia J, Cox WI, McNamara J, Hwang KL, Bradney A, Montefiori D, Weinhold KJ. Belshe RB, et al. AIDS. 1998 Dec 24;12(18):2407-15. doi: 10.1097/00002030-199818000-00009. AIDS. 1998. PMID: 9875578 Clinical Trial.
• HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
  Gorse GJ, Corey L, Patel GB, Mandava M, Hsieh RH, Matthews TJ, Walker MC, McElrath MJ, Berman PW, Eibl MM, Belshe RB. Gorse GJ, et al. AIDS Res Hum Retroviruses. 1999 Jan 20;15(2):115-32. doi: 10.1089/088922299311547. AIDS Res Hum Retroviruses. 1999. PMID: 10029244 Clinical Trial.
• Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida.
  Salmon-Céron D, Excler JL, Finkielsztejn L, Autran B, Gluckman JC, Sicard D, Matthews TJ, Meignier B, Valentin C, El Habib R, Blondeau C, Raux M, Moog C, Tartaglia J, Chong P, Klein M, Milcamps B, Heshmati F, Plotkin S. Salmon-Céron D, et al. AIDS Res Hum Retroviruses. 1999 May 1;15(7):633-45. doi: 10.1089/088922299310935. AIDS Res Hum Retroviruses. 1999. PMID: 10331442 Clinical Trial.
• Human studies in the development of human immunodeficiency virus vaccines.
  Dolin R. Dolin R. J Infect Dis. 1995 Nov;172(5):1175-83. doi: 10.1093/infdis/172.5.1175. J Infect Dis. 1995. PMID: 7594651 Review.
• Optimization of live oral Salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses.
  Hone DM, Wu S, Powell RJ, Pascual DW, Van Cott J, McGhee J, Fouts TR, Tuskan RG, Lewis GK. Hone DM, et al. J Biotechnol. 1996 Jan 26;44(1-3):203-7. doi: 10.1016/0168-1656(95)00151-4. J Biotechnol. 1996. PMID: 8717405 Review.

Cited by

• Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects.
  Kaur A, Vaccari M. Kaur A, et al. Viruses. 2024 Feb 27;16(3):368. doi: 10.3390/v16030368. Viruses. 2024. PMID: 38543734 Free PMC article. Review.
• Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines.
  Cohen G, Jungsomsri P, Sangwongwanich J, Tawinprai K, Siripongboonsitti T, Porntharukchareon T, Wittayasak K, Thonwirak N, Soonklang K, Sornsamdang G, Auewarakul C, Mahanonda N. Cohen G, et al. Hum Vaccin Immunother. 2022 Nov 30;18(5):2052525. doi: 10.1080/21645515.2022.2052525. Epub 2022 Mar 24. Hum Vaccin Immunother. 2022. PMID: 35323079 Free PMC article.
• Construction of a recombinant avipoxvirus expressing the env gene of Zika virus as a novel putative preventive vaccine.
  Zanotto C, Paolini F, Radaelli A, De Giuli Morghen C. Zanotto C, et al. Virol J. 2021 Mar 4;18(1):50. doi: 10.1186/s12985-021-01519-x. Virol J. 2021. PMID: 33663531 Free PMC article.
• Fowlpoxvirus recombinants coding for the CIITA gene increase the expression of endogenous MHC-II and Fowlpox Gag/Pro and Env SIV transgenes.
  Bissa M, Forlani G, Zanotto C, Tosi G, De Giuli Morghen C, Accolla RS, Radaelli A. Bissa M, et al. PLoS One. 2018 Jan 31;13(1):e0190869. doi: 10.1371/journal.pone.0190869. eCollection 2018. PLoS One. 2018. PMID: 29385169 Free PMC article.
• HIV-Specific Antibody-Dependent Cellular Cytotoxicity (ADCC) -Mediating Antibodies Decline while NK Cell Function Increases during Antiretroviral Therapy (ART).
  Jensen SS, Fomsgaard A, Borggren M, Tingstedt JL, Gerstoft J, Kronborg G, Rasmussen LD, Pedersen C, Karlsson I. Jensen SS, et al. PLoS One. 2015 Dec 22;10(12):e0145249. doi: 10.1371/journal.pone.0145249. eCollection 2015. PLoS One. 2015. PMID: 26696395 Free PMC article. Clinical Trial.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program